sorafenib has been researched along with cyclin d1 in 29 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (17.24) | 29.6817 |
| 2010's | 23 (79.31) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Heim, M; Jaehde, U; Scharifi, M; Seeber, S; Strumberg, D; Voliotis, D; Zisowsky, J | 1 |
| Cerniglia, G; Dicker, DT; Diehl, JA; Dorsey, JF; El-Deiry, WS; Flaherty, KT; Gupta, A; Kim, SH; Liu, YY; McDonough, J; Plastaras, JP; Rajendran, RR; Rustgi, AK; Smith, CD | 1 |
| Ambrosini, G; Cheema, HS; Sambol, EB; Schwartz, GK; Seelman, S; Singer, S; Teed, A | 1 |
| Bissonnette, M; Cerda, S; Chumsangsri, A; Delgado, JS; Dougherty, U; Fichera, A; Lichtenstein, L; Mustafi, R; Yee, J | 1 |
| Guo, W; Ji, T; Li, DS; Li, X; Peng, CL; Qu, HY; Ren, T; Tang, S; Tang, XD; Yan, TQ; Yang, Y | 1 |
| Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG | 1 |
| Brown, C; Buettner, R; Hedvat, M; Jensen, M; Jove, R; Schroeder, A; Scuto, A; Starr, R; Yang, F | 1 |
| Guo, W; Lu, X; Ren, T; Tang, X; Zhao, H | 1 |
| Buckley, M; Christos, PJ; Goldberg, L; Hamilton, A; Liebes, L; Min, C; Osman, I; Ott, PA; Pavlick, AC; Polsky, D; Safarzadeh-Amiri, S; Wright, JJ; Yee, H; Yoon, J | 1 |
| Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ; Xiong, MJ | 1 |
| Cohen, JD; Gallegos, AC; Lau, SS; Mastrandrea, NJ; Monks, TJ; Tham, KY | 1 |
| Broneshter, R; Iancu, TC; Manov, I; Pollak, Y | 1 |
| Culig, Z; Erb, HH; Hobisch, A; Oh, SJ; Santer, FR | 1 |
| Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Navarro, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S | 1 |
| Chen, KF; Cheng, AL; Hsieh, CY; Huang, CY; Lin, CS; Shiau, CW; Tai, WT | 1 |
| Banerjee, P; Begum, S; Castellanos, MR; Debata, PR; Genzer, O; Kleiner, MJ; Mata, A | 1 |
| Chen, W; Deng, J; Li, X; Wu, XY; Zhang, L; Zhang, YN; Zhong, CJ; Zhong, N | 1 |
| Deng, LF; Jia, QA; Li, JH; Ren, ZG; Shen, HJ; Sun, XJ; Wang, YH | 1 |
| Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H | 1 |
| Bao, J; Che, S; Hao, C; Li, Z; Liu, J; Qian, Z; Shang, H; Wang, H; Zhang, H; Zhang, X; Zhao, H | 1 |
| Chua, MS; Lu, WJ; So, SK; Wei, W | 1 |
| Fukunaga, K; Iwasaki, K; Kohno, K; Kurokawa, T; Murata, S; Ohkohchi, N; Zheng, YW | 1 |
| Abd El-Fattah, EE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, EG | 1 |
| He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
| Ammoun, S; Evans, DG; Hanemann, CO; Hayward, C; Hilton, DA; Streeter, A | 1 |
| Chen, D; Huang, Y; Lian, Y; Wang, J; Wei, H; Zeng, G | 1 |
| Ghanim, AMH; Saber, S; Younis, NS | 1 |
| Gong, Y; Huang, T; Huang, X; Liu, B; Wang, J; Wang, Z; Yu, Q | 1 |
1 trial(s) available for sorafenib and cyclin d1
| Article | Year |
|---|---|
A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cyclin D1; DNA Mutational Analysis; Female; Humans; Ki-67 Antigen; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sequence Analysis, DNA; Signal Transduction; Sorafenib | 2010 |
28 other study(ies) available for sorafenib and cyclin d1
| Article | Year |
|---|---|
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA Adducts; Drug Antagonism; Humans; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib | 2005 |
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Cell Growth Processes; Colorectal Neoplasms; Combined Modality Therapy; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Radiation; Drug Administration Schedule; Endothelial Cells; Female; G2 Phase; HCT116 Cells; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Retinoblastoma Protein; Sorafenib; Xenograft Model Antitumor Assays | 2007 |
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Differentiation; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Gene Silencing; Humans; Liposarcoma; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nerve Sheath Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib | 2008 |
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Sorafenib; STAT3 Transcription Factor | 2008 |
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Humans; In Situ Nick-End Labeling; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Retinoblastoma Protein; S Phase; Sarcoma, Synovial; Signal Transduction; Sorafenib | 2009 |
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Aromatase; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Caspase 7; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Niacinamide; Nitriles; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Testosterone; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazoles | 2010 |
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin E; DNA, Neoplasm; Glioblastoma; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Mutant Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Proteins; Phenylurea Compounds; Phosphorylation; Phosphotyrosine; Protein Binding; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Cells, Cultured; Vanadates | 2010 |
Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Cyclin D1; Extracellular Signal-Regulated MAP Kinases; Humans; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2010 |
[Sorafenib induces apoptosis of U937 cells via inhibiting WNT signal pathway].
Topics: Apoptosis; Benzenesulfonates; beta Catenin; Cell Proliferation; Cyclin D1; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; U937 Cells; Wnt Signaling Pathway | 2011 |
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Topics: Animals; Benzenesulfonates; Bucladesine; Carcinoma, Renal Cell; Cell Line; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Hydroquinones; Kidney Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Niacinamide; Pentoxifylline; Phenylurea Compounds; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Rats; RNA, Small Interfering; Signal Transduction; Sorafenib; Theophylline; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2011 |
Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Doxorubicin; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitochondria, Liver; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2011 |
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Down-Regulation; Humans; Male; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sorafenib | 2012 |
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclin D1; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins c-bcl-2; Receptors, Antigen, B-Cell; Signal Transduction; Sorafenib; Stromal Cells; Transplantation, Heterologous | 2013 |
Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Chemoradiotherapy; Cyclin D1; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Sorafenib; STAT3 Transcription Factor; Survivin | 2013 |
Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O: rapid inhibition of Rb phosphorylation as a preamble to cyclin D1 inhibition.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Curcumin; Cyclin D1; Cyclin-Dependent Kinase 4; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Retinoblastoma Protein; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib | 2014 |
[Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Topics: Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Antagonism; Fluorouracil; Humans; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2013 |
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; RNA Interference; Signal Transduction; Sorafenib; Time Factors; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; COP9 Signalosome Complex; Cyclin D1; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Integrin beta1; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; NF-kappa B; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2015 |
NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Doxycycline; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mice, Nude; Microscopy, Fluorescence; Niacinamide; Nuclear Receptor Subfamily 4, Group A, Member 1; Phenylurea Compounds; Protein Binding; Proteolysis; RNA Interference; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The Eltrombopag antitumor effect on hepatocellular carcinoma.
Topics: Apoptosis; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazines; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Receptors, Thrombopoietin; Sorafenib | 2015 |
Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Cyclin D1; Disease Models, Animal; Glutathione; Histocytochemistry; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rats; Sorafenib; Treatment Outcome | 2017 |
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Humans; Interferons; Interleukins; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice, Nude; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2017 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2.
Topics: Adult; Antineoplastic Agents; Blotting, Western; Caspase 3; Cyclin D1; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Neurofibromatosis 2; Proto-Oncogene Proteins c-akt; Receptor, Platelet-Derived Growth Factor beta; Ribosomal Protein S6; Sorafenib | 2019 |
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Models, Biological; Piperidines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Sorafenib; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2019 |
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Liver Neoplasms; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Mebendazole; Mice; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden; Vascular Endothelial Growth Factor A | 2019 |
Sorafenib suppresses proliferation rate of fibroblast-like synoviocytes through the arrest of cell cycle in experimental adjuvant arthritis.
Topics: Animals; Antirheumatic Agents; Apoptosis; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Down-Regulation; Fibroblasts; G1 Phase Cell Cycle Checkpoints; Hyperplasia; Mice; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Sorafenib; Synovial Membrane; Synoviocytes | 2021 |